{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:22:16Z","timestamp":1792214536293,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7182","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1038\/nature06633","type":"journal-article","created":{"date-parts":[[2008,2,10]],"date-time":"2008-02-10T12:58:27Z","timestamp":1202648307000},"page":"1116-1120","source":"Crossref","is-referenced-by-count":959,"title":["Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers"],"prefix":"10.1038","volume":"451","author":[{"given":"Wataru","family":"Sakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Y.","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh K.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Jacquemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Farrugia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergus J.","family":"Couch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyasu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,2,10]]},"reference":[{"key":"BFnature06633_CR1","first-page":"3547","volume":"59","author":"SS Yuan","year":"1999","unstructured":"Yuan, S. S. et al. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res. 59, 3547\u20133551 (1999)","journal-title":"Cancer Res."},{"key":"BFnature06633_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal, R. & Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature Rev. Cancer 3, 502\u2013516 (2003)","journal-title":"Nature Rev. Cancer"},{"key":"BFnature06633_CR3","first-page":"5360","volume":"56","author":"M Goggins","year":"1996","unstructured":"Goggins, M. et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 56, 5360\u20135364 (1996)","journal-title":"Cancer Res."},{"key":"BFnature06633_CR4","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/jnci\/90.13.978","volume":"90","author":"DW Abbott","year":"1998","unstructured":"Abbott, D. W., Freeman, M. L. & Holt, J. T. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J. Natl Cancer Inst. 90, 978\u2013985 (1998)","journal-title":"J. Natl Cancer Inst."},{"key":"BFnature06633_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11912-001-0039-y","volume":"3","author":"AJ Li","year":"2001","unstructured":"Li, A. J. & Karlan, B. Y. Genetic factors in ovarian carcinoma. Curr. Oncol. Rep. 3, 27\u201332 (2001)","journal-title":"Curr. Oncol. Rep."},{"key":"BFnature06633_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/jmg.2004.028829","volume":"42","author":"CJ van Asperen","year":"2005","unstructured":"van Asperen, C. J. et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J. Med. Genet. 42, 711\u2013719 (2005)","journal-title":"J. Med. Genet."},{"key":"BFnature06633_CR7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1126\/science.1073834","volume":"297","author":"NG Howlett","year":"2002","unstructured":"Howlett, N. G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606\u2013609 (2002)","journal-title":"Science"},{"key":"BFnature06633_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1097-2765(01)00174-5","volume":"7","author":"ME Moynahan","year":"2001","unstructured":"Moynahan, M. E., Pierce, A. J. & Jasin, M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell 7, 263\u2013272 (2001)","journal-title":"Mol. Cell"},{"key":"BFnature06633_CR9","first-page":"6069","volume":"54","author":"SL Neuhausen","year":"1994","unstructured":"Neuhausen, S. L. & Marshall, C. J. Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res. 54, 6069\u20136072 (1994)","journal-title":"Cancer Res."},{"key":"BFnature06633_CR10","first-page":"1673","volume":"10","author":"N Collins","year":"1995","unstructured":"Collins, N. et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12\u201313. Oncogene 10, 1673\u20131675 (1995)","journal-title":"Oncogene"},{"key":"BFnature06633_CR11","first-page":"4830","volume":"55","author":"J Gudmundsson","year":"1995","unstructured":"Gudmundsson, J. et al. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12\u2013q13. Cancer Res. 55, 4830\u20134832 (1995)","journal-title":"Cancer Res."},{"key":"BFnature06633_CR12","doi-asserted-by":"publisher","first-page":"23899","DOI":"10.1074\/jbc.C000276200","volume":"275","author":"A Bhattacharyya","year":"2000","unstructured":"Bhattacharyya, A., Ear, U. S., Koller, B. H., Weichselbaum, R. R. & Bishop, D. K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275, 23899\u201323903 (2000)","journal-title":"J. Biol. Chem."},{"key":"BFnature06633_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1101\/sqb.2005.70.012","volume":"70","author":"AN Tutt","year":"2005","unstructured":"Tutt, A. N. et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol. 70, 139\u2013148 (2005)","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"BFnature06633_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10689-005-2832-5","volume":"5","author":"WD Foulkes","year":"2006","unstructured":"Foulkes, W. D. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam. Cancer 5, 135\u2013142 (2006)","journal-title":"Fam. Cancer"},{"key":"BFnature06633_CR15","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","volume":"283","author":"J Boyd","year":"2000","unstructured":"Boyd, J. et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. J. Am. Med. Assoc. 283, 2260\u20132265 (2000)","journal-title":"J. Am. Med. Assoc."},{"key":"BFnature06633_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/jmg.40.10.721","volume":"40","author":"R Hirschhorn","year":"2003","unstructured":"Hirschhorn, R. In vivo reversion to normal of inherited mutations in humans. J. Med. Genet. 40, 721\u2013728 (2003)","journal-title":"J. Med. Genet."},{"key":"BFnature06633_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1365-2141.2005.05916.x","volume":"132","author":"S Hamanoue","year":"2006","unstructured":"Hamanoue, S. et al. Myeloid lineage-selective growth of revertant cells in Fanconi anaemia. Br. J. Haematol. 132, 630\u2013635 (2006)","journal-title":"Br. J. Haematol."},{"key":"BFnature06633_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/ng1942","volume":"39","author":"B Xia","year":"2007","unstructured":"Xia, B. et al. Fanconi anaemia is associated with a defect in the BRCA2 partner PALB2. Nature Genet. 39, 159\u2013161 (2007)","journal-title":"Nature Genet."},{"key":"BFnature06633_CR19","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L","volume":"78","author":"AF Gazdar","year":"1998","unstructured":"Gazdar, A. F. et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78, 766\u2013774 (1998)","journal-title":"Int. J. Cancer"},{"key":"BFnature06633_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/ng0596-126","volume":"13","author":"S Neuhausen","year":"1996","unstructured":"Neuhausen, S. et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genet. 13, 126\u2013128 (1996)","journal-title":"Nature Genet."},{"key":"BFnature06633_CR21","doi-asserted-by":"publisher","first-page":"8768","DOI":"10.1073\/pnas.0600298103","volume":"103","author":"H Saeki","year":"2006","unstructured":"Saeki, H. et al. Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions. Proc. Natl Acad. Sci. USA 103, 8768\u20138773 (2006)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature06633_CR22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/0008-5472.417.65.2","volume":"65","author":"K Wu","year":"2005","unstructured":"Wu, K. et al. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res. 65, 417\u2013426 (2005)","journal-title":"Cancer Res."},{"key":"BFnature06633_CR23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005)","journal-title":"Nature"},{"key":"BFnature06633_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917 (2005)","journal-title":"Nature"},{"key":"BFnature06633_CR25","doi-asserted-by":"publisher","first-page":"7395","DOI":"10.1158\/0008-5472.CAN-07-1015","volume":"67","author":"C Jacquemont","year":"2007","unstructured":"Jacquemont, C. & Taniguchi, T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res. 67, 7395\u20137405 (2007)","journal-title":"Cancer Res."},{"key":"BFnature06633_CR26","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1093\/emboj\/20.17.4704","volume":"20","author":"A Tutt","year":"2001","unstructured":"Tutt, A. et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 20, 4704\u20134716 (2001)","journal-title":"EMBO J."},{"key":"BFnature06633_CR27","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/jnci\/94.18.1396","volume":"94","author":"JL Hilton","year":"2002","unstructured":"Hilton, J. L. et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J. Natl. Cancer Inst. 94, 1396\u20131406 (2002)","journal-title":"J. Natl. Cancer Inst."},{"key":"BFnature06633_CR28","first-page":"2688","volume":"63","author":"H Ikeda","year":"2003","unstructured":"Ikeda, H. et al. Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. Cancer Res. 63, 2688\u20132694 (2003)","journal-title":"Cancer Res."},{"key":"BFnature06633_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.mrfmmm.2006.03.001","volume":"600","author":"WW Wiegant","year":"2006","unstructured":"Wiegant, W. W., Overmeer, R. M., Godthelp, B. C., van Buul, P. P. & Zdzienicka, M. Z. Chinese hamster cell mutant, V-C8, a model for analysis of Brca2 function. Mutat. Res. 600, 79\u201388 (2006)","journal-title":"Mutat. Res."},{"key":"BFnature06633_CR30","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876\u2013880 (2001)","journal-title":"Science"},{"key":"BFnature06633_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nm852","volume":"9","author":"T Taniguchi","year":"2003","unstructured":"Taniguchi, T. et al. Disruption of the Fanconi anemia\u2013BRCA pathway in cisplatin-sensitive ovarian tumors. Nature Med. 9, 568\u2013574 (2003)","journal-title":"Nature Med."},{"key":"BFnature06633_CR32","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1097-2765(01)00173-3","volume":"7","author":"I Garcia-Higuera","year":"2001","unstructured":"Garcia-Higuera, I. et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7, 249\u2013262 (2001)","journal-title":"Mol. Cell"},{"key":"BFnature06633_CR33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0092-8674(02)00747-X","volume":"109","author":"T Taniguchi","year":"2002","unstructured":"Taniguchi, T. et al. Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. Cell 109, 459\u2013472 (2002)","journal-title":"Cell"},{"key":"BFnature06633_CR34","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-05-0493","volume":"5","author":"D Chirnomas","year":"2006","unstructured":"Chirnomas, D. et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia\/BRCA pathway. Mol. Cancer Ther. 5, 952\u2013961 (2006)","journal-title":"Mol. Cancer Ther."},{"key":"BFnature06633_CR35","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1128\/MCB.18.10.5952","volume":"18","author":"D Naf","year":"1998","unstructured":"Naf, D., Kupfer, G. M., Suliman, A., Lambert, K. & D\u2019Andrea, A. D. Functional activity of the fanconi anemia protein FAA requires FAC binding and nuclear localization. Mol. Cell. Biol. 18, 5952\u20135960 (1998)","journal-title":"Mol. Cell. Biol."},{"key":"BFnature06633_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1021\/jm0255769","volume":"46","author":"DJ Skalitzky","year":"2003","unstructured":"Skalitzky, D. J. et al. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J. Med. Chem. 46, 210\u2013213 (2003)","journal-title":"J. Med. Chem."},{"key":"BFnature06633_CR37","doi-asserted-by":"publisher","first-page":"6712","DOI":"10.1073\/pnas.91.14.6712","volume":"91","author":"T Yamashita","year":"1994","unstructured":"Yamashita, T., Barber, D. L., Zhu, Y., Wu, N. & D\u2019Andrea, A. D. The Fanconi anemia polypeptide FACC is localized to the cytoplasm. Proc. Natl Acad. Sci. USA 91, 6712\u20136716 (1994)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature06633_CR38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S1568-7864(03)00112-5","volume":"2","author":"D Bruun","year":"2003","unstructured":"Bruun, D. et al. siRNA depletion of BRCA1, but not BRCA2, causes increased genome instability in Fanconi anemia cells. DNA Repair 2, 1007\u20131013 (2003)","journal-title":"DNA Repair"},{"key":"BFnature06633_CR39","first-page":"303","volume-title":"Genome Analysis: A Laboratory Manual","author":"BJ Trask","year":"1999","unstructured":"Trask, B. J. in Genome Analysis: A Laboratory Manual (eds Birren, B. et al.), vol. 4 303\u2013413 (Cold Spring Harbor Laboratory Press, New York, 1999)"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nature06633","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature06633.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nature06633.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:13:41Z","timestamp":1684419221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature06633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":39,"journal-issue":{"issue":"7182","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["BFnature06633"],"URL":"https:\/\/doi.org\/10.1038\/nature06633","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}